Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22127898 | 1.00 | KMT2A (0.57) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL22127752 | 0.97 | KMT2A (0.59) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL22127753 | 0.97 | KMT2A (0.59) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL22127844 | 0.90 | KMT2A (0.61) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL29482638 | 0.90 | KMT2A (0.61) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL22127873 | 0.90 | KMT2A (0.61) | KMT2AEPHX2CASP3DOT1LTLR2 | |
| SCHEMBL30887302 | 0.87 | KMT2A (0.63) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL12972620 | 0.87 | KMT2A (0.63) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL15160784 | 0.87 | KMT2A (0.63) | KMT2AEPHX2CASP3TLR2 | |
| SCHEMBL14682729 | 0.87 | KMT2A (0.63) | KMT2AEPHX2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988561-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| CN-115475229-A | Preparation and use of active oxygen scavenger | 凯瑞康宁生物工程（武汉）有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-111356699-B | Preparation and use of active oxygen scavenger | 凯瑞康宁生物工程（武汉）有限公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-3988561-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2022-04-27 | — | — | EP | disclosed |
| EP-3679051-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2021-12-29 | — | — | EP | disclosed |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | XWPharma Ltd. (KY) | 2021-03-04 | — | — | US | disclosed |
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | XW LABORATORIES INC. (KY) | 2021-01-12 | — | — | US | disclosed |
| CN-111356699-A | Preparation and use of active oxygen scavenger | 凯瑞康宁生物工程（武汉）有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | KMT2A 4439/4885EPHX2 848/4885CASP3 868/4885 |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | GSR, TXNRD2, GPX1 | KMT2A 4439/4885EPHX2 848/4885CASP3 868/4885 |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | GPX1, SOD1, GPX4 | KMT2A 4630/4885EPHX2 714/4885CASP3 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.